Abstract: A tuned mass damper (TMD) system in combination with a floating offshore wind turbine (FOWT) platform includes a barge type FOWT platform having a hull configured to have a wind turbine tower mounted thereon. A TMD system is mounted in the hull and has a first TMD configured to operate at a first frequency, and a second TMD configured to operate at a second frequency different than the first frequency.

Abstract: Disclosed herein is a biomimetic coating for use in a microfluidic channel to capture rare cells from a sample while maintaining the viability of the captured cells.

Abstract: This invention concerns patentable devices configured to capture cancer stem cells and cell clusters. After capturing such cells and/or clusters, the cancerous cells are subjected to whole genome sequencing. The resulting genomic sequence information is then compared to that for “normal” or non-diseased tissue (obtained, for example, from either the same patient, or a population sample, etc.) in order to identify the specific genetic mutation(s) present in the CSCs. Further analysis then correlates the genetic mutations with cell growth signaling pathways typically found with tumor metastases. Armed with this information, an oncologist can then develop a specifically targeted therapy that utilizes approved drugs or drug candidates undergoing clinical testing to address the identified driver mutations and thus effect a “targeted” therapy tailored to the particular patient's disease.

Abstract: This invention concerns patentable devices configured to capture cancer stem cells and cell clusters. After capturing such cells and/or clusters, the cancerous cells are subjected to whole genome sequencing. The resulting genomic sequence information is then compared to that for “normal” or non-diseased tissue (obtained, for example, from either the same patient, or a population sample, etc.) in order to identify the specific genetic mutation(s) present in the CSCs. Further analysis then correlates the genetic mutations with cell growth signaling pathways typically found with tumor metastases. Armed with this information, an oncologist can then develop a specifically targeted therapy that utilizes approved drugs or drug candidates undergoing clinical testing to address the identified driver mutations and thus effect a “targeted” therapy tailored to the particular patient's disease.